A Two-part, Randomised, Open-label, Multicentre, Phase I Study to Determine the Effect of Food on the Pharmacokinetics of Olaparib Following Single 400 mg Doses of the Capsule Formulation in Patients With Advanced Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 31 Aug 2017
At a glance
- Drugs Olaparib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 25 Aug 2017 Status changed from active, no longer recruiting to completed.
- 21 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 26 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016, as reported by ClinicalTrials.gov record.